Fig. 1

Heterogeneity of the CD10⁺ cell population. a FACS analysis of CD10⁺ cells according to expression of CD44 in normal breast tissues of nulliparous (NP) and parous (P) control women and BRCA1 and BRCA2 mutation carriers. b Quantification of percentage of CD10⁺CD44⁻ and CD10⁺CD44⁺ in total epithelial cells (n = 6/group). p-values indicate statistical significance of difference in total CD10⁺ cells between groups by t-test. c viSNE maps from CyTOF analysis of normal breast tissues colored for expression of SMA, CD10, CD44, and CD49f (control n = 6, BRCA1 n = 6, BRCA2 n = 7). Color scale indicates minimum and maximum values of expression. d Pathways enriched in genes differentially expressed between CD10⁺CD44⁻ and CD10⁺CD44⁺ cells. Color scale corresponds to −log(p-value) of significance of enrichment, calculated by MetaCore Enrichment Analysis test. e 3D Principal component analysis plots of CD10⁺ gene expression data from the indicated samples. f Transcription factors differentially expressed between CD10⁺CD44⁻ and CD10⁺CD44⁺ cells. Red highlight indicates genes selected for further analyses. g Multicolor immunofluorescence analysis of p63, TCF7, and CD10 expression in normal breast tissues. Images are a montage of nine fields captured from one area of the tissue. Scale bar 50 μm. h Relative quantification of CD10⁺ myoepithelial cells positive for p63 or TCF7 or both proteins. p-value indicates the significant association of the p63/TCF7 positive/negative status of CD10⁺ myoepithelial cells with condition (Control, BRCA1, or BRCA2), as assessed by Pearson’s chi-squared test among averages of estimated cell counts across replicates (total population size was conservatively estimated to 100 cells). Source data are provided as a Source Data file